4-[(1S)-2-[(3R)-4-[2-chloro-4-(2-hydroxyethoxy)phenyl]-3-(4-chlorophenyl)-5-oxopiperazin-1-yl]-1-hydroxyethyl]benzonitrile | 1097207-49-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-[(1S)-2-[(3R)-4-[2-chloro-4-(2-hydroxyethoxy)phenyl]-3-(4-chlorophenyl)-5-oxopiperazin-1-yl]-1-hydroxyethyl]benzonitrile
• CAS: 1097207-49-2
• 化学式: C₂₇H₂₅Cl₂N₃O₄
• 分子量: 526.419
• InChiKey: MSMWOKHSDMWCGL-IZZNHLLZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  97
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Substituted Piperazines as CB1 Antagonists
  申请人：Gilbert Eric J.

  公开号：US20090105208A1

  公开（公告）日：2009-04-23

  Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB 1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  式(I)的化合物或其药学上可接受的盐、溶剂化物或酯类，可用于治疗由CB1受体介导的疾病或症状，例如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾（例如戒烟）、胃肠疾病和心血管疾病。
• Substituted piperazines as CB1 antagonists
  申请人：Intervet International B.V.

  公开号：EP2548874A2

  公开（公告）日：2013-01-23

  Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB, receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  式 (I) 的化合物： 或其药学上可接受的盐、溶液剂或酯类，可用于治疗由 CB 受体介导的疾病或病症，如代谢综合征和肥胖症、神经炎性疾病、认知障碍和精神病、成瘾（如戒烟）、胃肠道疾病和心血管疾病。
• US8623873B2
  申请人：——

  公开号：US8623873B2

  公开（公告）日：2014-01-07
• [EN] SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS<br/>[FR] PIPÉRAZINES À SUBSTITUTION SERVANT D'ANTAGONISTES DES RÉCEPTEURS CB1
  申请人：SCHERING CORP

  公开号：WO2009005646A2

  公开（公告）日：2009-01-08

  Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.